These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 24370228)
1. [Impact of gender on lipoprotein-associated phospholipase A2 activity and association with known cardiovascularrisk factors]. Jia ZR; Zhao D; Qi Y; Wang W; Wang M; Sun JY; Qin LP; Liu J Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Nov; 41(11):962-7. PubMed ID: 24370228 [TBL] [Abstract][Full Text] [Related]
2. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676 [TBL] [Abstract][Full Text] [Related]
4. [Association of lipoprotein-associated phospholipase activity A2 with cardiovascular risk factors]. Acevedo M; Varleta P; Kramer V; Quiroga T; Prieto C; Parada J; Adasme M; Briones L; Navarrete C Rev Med Chil; 2013 Nov; 141(11):1382-8. PubMed ID: 24718463 [TBL] [Abstract][Full Text] [Related]
5. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Persson M; Nilsson JA; Nelson JJ; Hedblad B; Berglund G Atherosclerosis; 2007 Feb; 190(2):388-96. PubMed ID: 16530769 [TBL] [Abstract][Full Text] [Related]
6. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Noto H; Chitkara P; Raskin P J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436 [TBL] [Abstract][Full Text] [Related]
8. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
9. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature. Gregson J; Stirnadel-Farrant HA; Doobaree IU; Koro C Atherosclerosis; 2012 Nov; 225(1):11-21. PubMed ID: 22784637 [TBL] [Abstract][Full Text] [Related]
10. Dual activity of serum lipoprotein-associated phospholipase A(2) yielding positive and inverse associations with cardiometabolic risk. Onat A; Hergenç G; Can G; Uğur M; Nartop F Clin Chem Lab Med; 2011 Aug; 49(8):1349-1357. PubMed ID: 21756164 [TBL] [Abstract][Full Text] [Related]
11. Association of lipoprotein-associated phospholipase A₂ activity with components of the metabolic syndrome in apparently healthy boys. Hirschler V; Meroño T; Maccallini G; Gomez Rosso L; Aranda C; Brites F Cardiovasc Hematol Agents Med Chem; 2011 Apr; 9(2):78-83. PubMed ID: 21476960 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096 [TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783 [TBL] [Abstract][Full Text] [Related]
14. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. Chae JS; Kim OY; Paik JK; Kang R; Seo WJ; Jeong TS; Sweeney G; Lee SH; Lee JH Atherosclerosis; 2011 Oct; 218(2):499-506. PubMed ID: 21762913 [TBL] [Abstract][Full Text] [Related]
15. Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium. Constantinides A; Kerstens MN; Dikkeschei BD; van Pelt LJ; Tellis CC; Tselepis AD; Dullaart RP Eur J Clin Invest; 2012 Nov; 42(11):1235-43. PubMed ID: 22957745 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668 [TBL] [Abstract][Full Text] [Related]
17. The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. Jang Y; Kim OY; Koh SJ; Chae JS; Ko YG; Kim JY; Cho H; Jeong TS; Lee WS; Ordovas JM; Lee JH J Clin Endocrinol Metab; 2006 Sep; 91(9):3521-7. PubMed ID: 16787988 [TBL] [Abstract][Full Text] [Related]
18. Interrelationships among platelet-activating factor and lipoprotein-associated phospholipase A English CJ; Lohning AE; Mayr HL; Jones M; Reidlinger DP Biofactors; 2023 Mar; 49(2):457-471. PubMed ID: 36538603 [TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Chu AY; Guilianini F; Grallert H; Dupuis J; Ballantyne CM; Barratt BJ; Nyberg F; Chasman DI; Ridker PM Circ Cardiovasc Genet; 2012 Dec; 5(6):676-85. PubMed ID: 23118302 [TBL] [Abstract][Full Text] [Related]